Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.
The ASX healthcare sector ended the week ending November 21, 2025 down, following a sharp sell-off as on Wall Street and ...
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage ...
Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...
Newser on MSN
Pfizer's New Flu Shot Could Be a 'Game Changer'
A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...
On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...
Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...
Zacks Investment Research on MSN
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase III VANQUISH-1 study, ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback